EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 2

Ensembl ID : ENSSAUG00010020121
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 6

Ensembl ID : ENSSAUG00010006993
Gene Symbol: PSMD6
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 7

Ensembl ID : ENSSAUG00010023937
Gene Symbol: PSMD7
3 Cross references
235 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSSAUG00010021649
Gene Symbol: PSMD8
3 Cross references
211 Possible Orthologues:

Proteasome Subunit Alpha Type-4

Ensembl ID : ENSSAUG00010017501
Gene Symbol: LOC115587350
3 Cross references
186 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSSAUG00010018769
Gene Symbol: PSMB11
1 Cross references
169 Possible Orthologues:

Proteasome Subunit Beta Type-11-Like

Ensembl ID : ENSSAUG00010015241
Gene Symbol: LOC115591525
3 Cross references
159 Possible Orthologues:

Proteasome Subunit Beta Type-4-Like

Ensembl ID : ENSSAUG00010007698
Gene Symbol: LOC115577670
3 Cross references
213 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSSAUG00010002994
Gene Symbol: LOC115577607
3 Cross references
230 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSSAUG00010011974
Gene Symbol: LOC115593311
3 Cross references
171 Possible Orthologues:

Proteasome Subunit Beta Type-8-Like

Ensembl ID : ENSSAUG00010020623
Gene Symbol: LOC115579008
3 Cross references
218 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSSAUG00010020612
Gene Symbol: LOC115579015
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).